Long-Term Persistence of Mitochondrial DNA Instability among HCV-Cured People Who Inject Drugs
- PMID: 36289803
- PMCID: PMC9599189
- DOI: 10.3390/biomedicines10102541
Long-Term Persistence of Mitochondrial DNA Instability among HCV-Cured People Who Inject Drugs
Abstract
People who inject drugs (PWID) are a population exposed to many genotoxicants and with a high prevalence of HCV infection. Direct-acting antiviral (DAA) regimens are now widely used to treat chronic HCV infection. Although side effects to treatment are currently rare, the long-term effects such as suspicions of de novo hepatocellular carcinoma (HCC) occurrence or HCC recurrence and cardiac defects are still up for debate. Given the structure of DAAs, the molecules have a potential mitochondrial DNA (mtDNA) genotoxicity. We have previously reported acute mtDNA toxicity of three DAA regimens among PWID with a strong impact on the rate of mtDNA deletion, less on the quantity of mtDNA copy per cell at sustained viral response at 12 weeks (SVR12). Herein, we report the mtDNA parameters nine months after drug discontinuation. We observed that the percentage of the deleted mtDNA genome increased over time. No exposure to any other genotoxicants during this period was associated with a high deletion percentage, suggesting that the replicative advantage of the deleted molecules outweighed their elimination processes. Such observation calls for longer-term follow-up and may contribute to the molecular basis of subclinical side effects of DAA treatments.
Keywords: DAA; HCV; genotoxicity; mitochondria; side effect.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
References
-
- Hayes K.N., Burkard T., Weiler S., Tadrous M., Burden A.M. Global Adverse Events Reported for Direct-Acting Antiviral Therapies for the Treatment of Hepatitis C: An Analysis of the World Health Organization VigiBase. Eur. J. Gastroenterol. Hepatol. 2021;33:e1017–e1021. doi: 10.1097/MEG.0000000000002173. - DOI - PMC - PubMed
-
- Yahya G., Hashem Mohamed N., Pijuan J., Seleem N.M., Mosbah R., Hess S., Abdelmoaty A.A., Almeer R., Abdel-Daim M.M., Shulaywih Alshaman H., et al. Profiling the Physiological Pitfalls of Anti-Hepatitis C Direct-Acting Agents in Budding Yeast. Microb. Biotechnol. 2021;14:2199–2213. doi: 10.1111/1751-7915.13904. - DOI - PMC - PubMed
-
- Ehteshami M., Zhou L., Amiralaei S., Shelton J.R., Cho J.H., Zhang H., Li H., Lu X., Ozturk T., Stanton R., et al. Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase. Antimicrob. Agents Chemother. 2017;61:e00492-17. doi: 10.1128/AAC.00492-17. - DOI - PMC - PubMed
-
- Jin Z., Kinkade A., Behera I., Chaudhuri S., Tucker K., Dyatkina N., Rajwanshi V.K., Wang G., Jekle A., Smith D.B., et al. Structure-Activity Relationship Analysis of Mitochondrial Toxicity Caused by Antiviral Ribonucleoside Analogs. Antiviral. Res. 2017;143:151–161. doi: 10.1016/j.antiviral.2017.04.005. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources